The Korea Pharmaceutical Bio Association and the Korean Pharmaceutical Association will hold a joint symposium on the 22nd
Oct 02, 2025
|
This symposium, which will be held at the COEX Magok Convention Center in Gangseo-gu, Seoul, will be held during the '2025 Korean Pharmaceutical Association Autumn International Conference' under the theme of 'Technology Beyond Time, Changing the Future of Pharmaceutical Bio'.
The pre-registration of the symposium is until the 13th of this month, and it is available on the pre-registration tab of the 2025 Autumn International Academic Conference on the website of the Korean Pharmaceutical Association.
The symposium keynote speech presents how the antibody-drug conjugate (ADC) is changing the paradigm of new anticancer drug development through early clinical results of the Yoshinori Kawaguchi Daiichi-Sankyo T-DXd leader 'Enhutu'. It will be a place to look at innovative treatment development strategies that the industry should move forward in the future.
After that, the symposium will feature three sessions: new modality, new drug development using AI, and global clinical trial topics, and will be presented based on actual cases by representative companies in the field.
In the first session, chaired by Seo Hyung-seok, a professor at Seoul National University's College of Pharmacy, Dr. Lee Sang-hyun of Oreum Therapeutics and CEO of Qrocel Kim Soo-soo will introduce the 「Next-generation treatment innovation-new modality introduction case」, respectively.
The second session will be chaired by Han Sang-hee, head of the AI New Drug Research Institute of the Korea Pharmaceutical and Bio Association. Hanmi Pharmaceutical's managing director Jeon Hae-min and OncoCross CEO Kim I-rang will present 'AI-led new drug development innovation' focusing on empirical cases.
At the last session, chaired by Kim Soon-nam, head of the R&D division of the National New Drug Development Foundation, there will be a venue to disclose the `multi-national clinical strategies and achievements for global new drug development.' Park Jung-shin, vice president of SK Biopharmaceuticals, and Lee Seung-oh, head of Yuhan Corporation, will share their experiences.
This article was translated by Naver AI translator.
